Prognostication with Thyroid GuidePx in the context of tall cell variants

The tall cell variant of papillary thyroid cancer generally has a worse prognosis compared with the classical variant. Thyroid GuidePx is a genomic classifier capable of classifying papillary thyroid cancer into 3 molecular subtypes using fine-needle aspirate. Type 1 and 2 have low recurrence rates, particularly in early tumors (1–4 cm and N0). Type 3 is characterized by aggressive biology and high recurrence rates regardless of size and lymph node status. The study examines the interaction of tall cell variant histology with Thyroid GuidePx risk stratification.

Continue ReadingPrognostication with Thyroid GuidePx in the context of tall cell variants

Abstract: RAI GuidePx: A robust predictor for radioactive iodine sensitivity status in papillary thyroid cancer leveraging thyroid differentiation genes.

Abstract: 0539American Thyroid Association Annual MeetingOct 30 – Nov 3, 2024This is early work describing the development of an algorithm for predicting resistance to RAI. The internal validation is excellent,…

Continue ReadingAbstract: RAI GuidePx: A robust predictor for radioactive iodine sensitivity status in papillary thyroid cancer leveraging thyroid differentiation genes.

Abstract: Molecular subtypes in radiation induced papillary thyroid cancer using Thyroid GuidePx.

Abstract: 0551American Thyroid Association Annual MeetingOct 30 - Nov 3, 2024Here we wanted to explore whether the biology captured by our prognostic test, Thyroid GuidePx, was present in radiation induced…

Continue ReadingAbstract: Molecular subtypes in radiation induced papillary thyroid cancer using Thyroid GuidePx.

Radiofrequency Ablation: An Alternative Approach to Treating Papillary Thyroid Cancer

Radiofrequency Ablation: An Alternative Approach to Treating Papillary Thyroid Cancer Papillary thyroid cancer (PTC) is the most common type of thyroid cancer, and while surgery remains the primary treatment option,…

Continue ReadingRadiofrequency Ablation: An Alternative Approach to Treating Papillary Thyroid Cancer